参考文献/References:
[1]Levine DN,Brooks MB.Immune thrombocytopenia(ITP):Pathophysiology update and diagnostic dilemmas[J].Veterinary Clinical Pathology,2019,48(Suppl1):17-28. [2]Terrell DR,Beebe LA,Vesely SK,et al.The incidence of immune thrombocytopenic purpura in children and adults:A critical review of published reports[J].American Journal of Hematology,2010,85(3):174-180. [3]Moulis G,Palmaro A,Montastruc JL,et al.Epidemiology of incident immune thrombocytopenia:a nationwide population-based study in France[J].Blood,2014,124(22):3308. [4]Lee EJ,Lee AI.Thrombocytopenia[J].Prim Care,2016,43(4):543-557. [5]Hung GY,Lee CY,Yen HJ,et al.Incidence of immune thrombocytopenia in Taiwan:a nationwide population-based study[J].Transfusion,2018,58(11):2712-2719. [6]Marini I,Bakchoul T.Pathophysiology of Autoimmune Thrombocytopenia:Current Insight with a Focus on Thrombopoiesis[J].Hamostaseologie,2019,39(3):227-237. [7]Newland A,Lee EJ,Mcdonald V,et al.Fostamatinib for persistent/chronic adult immune thrombocytopenia[J].Immunotherapy,2018,10(1):9-25. [8]周正菊,张友山,梁彩霞,等.ITP患者外周血Th9、Th17和Treg细胞水平及IL-9、IL-17和TGF-β表达在ITP发病中的作用[J].中国实验血液学杂志,2019,27(1):180-184. [9]王明镜,许勇钢,丁晓庆,等.免疫性血小板减少症患者Th17/Treg细胞失衡与特异性转录因子表达异常[J].血栓与止血学,2018,24(6):901-904,908. [10]王琦,计雪强,邵惠江,等.免疫性血小板减少症(ITP)患儿外周血调节性T细胞数量减少伴随自噬的降低[J].细胞与分子免疫学杂志,2018,34(9):834-838. [11]Son BR,Kim JY.Association of CD4(+)CD25(+)FoxP3(+)regulatory T cells with natural course of childhood chronic immune thrombocytopenic purpura[J].Korean J Pediatr,2015,58(5):178-182. [12]Wang J,Li Y,Wang C,et al.Efficacy and Safety of the Combination Treatment of Rituximab and Dexamethasone for Adults with Primary Immune Thrombocytopenia(ITP):A Meta-Analysis[J].Biomed Research International,2018(2018):1316096. [13]Liu JX,Zhang HX,Li DP,et al.Curative Efficacy of Rituximab for ITP Patients with Different Sensitivity to Hormone[J].Journal of Experimental Hematology,2019,27(5):1602-1606. [14]Lu Y,Cheng L,Li F,et al.The abnormal function of CD39+regulatory T cells could be corrected by high-dose dexamethasone in patients with primary immune thrombocytopenia[J].Annals of Hematology,2019,98(8):1845-1854. [15]Wang S,Yang KD,Lin C,et al.Intravenous immunoglobulin therapy enhances suppressive regulatory T cells and decreases innate lymphoid cells in children with immune thrombocytopenia[J].Pediatric Blood&Cancer,2020,67(2):e28075. [16]梁兴林,夏瑞祥,曾庆曙,等.Breg Tfh Tfr细胞在免疫性血小板减少症患者中的表达及意义[J].安徽医学,2020,41(6):625-627. [17]刘兆玉,姜波.不同剂量地塞米松对免疫性血小板减少症疗效及调节性T细胞的影响[J].中国基层医药,2019,26(10):1250-1252. [18]刘伯轩.大剂量地塞米松对免疫性血小板减少症患者CD4+CD25+调节性T淋巴细胞水平的影响研究[J].临床研究,2020,28(10):116-117. [19]Sollazzo D,Polverelli N,Palandri F,et al.Circulating CD4+CD25-Foxp3+cells are increased in patients with immune thrombocytopenia[J].Immunol Lett,2015,166(1):63-64. [20]Wang Q,Li J,Yu TS,et al.Disrupted balance of CD4+T-cell subsets in bone marrow of patients with primary immune thrombocytopenia[J].International Journal of Biological Sciences,2019,15(13):2798-2814. [21]Song Y,Wang YT,Huang XJ,et al.Abnormalities of the bone marrow immune microenvironment in patients with immune thrombocytopenia[J].Annals of Hematology,2016,95(6):1-7. [22]Yu J,Heck S,Patel V,et al.Defective circulating CD25 regulatory T cells in patients with chronic immune thrombocytopenic purpura[J].Blood,2008,112(4):1325-1328. [23]Rodríguez-Perea AL,Arcia ED,Rueda CM,et al.Phenotypical characterization of regulatory T cells in humans and rodents[J].Clin Exp Immunol,2016,185(3):281-291. [24]Wolf SD,Dittel BN,Hardardottir F,et al.Experimental Autoimmune Encephalomyelitis Induction in Genetically B Cell deficient Mice[J].Journal of Experimental Medicine,1996,184(6):2271-2278. [25]Mizoguchi A,Mizoguchi E,Takedatsu H,et al.Chronic Intestinal Inflammatory Condition Generates IL-10-Producing Regulatory B Cell Subset Characterized by CD1d Upregulation[J].Immunity,2002,16(2):219-230. [26]Mizoguchi A,Bhan AK.A Case for Regulatory B Cells[J].The Journal of Immunology,2006,176(2):705-710. [27]Claudia M,Madhvi M.The expanding family of regulatory B cells[J].International Immunology,2015(10):10. [28]Zhu SR,Chen HY,Wang MJ,et al.Level of Regulatory B Cells in Patients with Immune Thrombocytopenia and Its Clinical Significance[J].Journal of Experimental Hematology,2019,27(1):175-179. [29]DI ZX,Geng Y,Sun XL,et al.Expression of CD19+B Cells and Involvement of Serum Breg in Pathogenesis of Immune Thrombocytopenia[J].Journal of Experimental Hematology,2019,27(3):911-915. [30]Fang J,Lin L,Lin D,et al.The imbalance between regulatory memory B cells reveals possible pathogenesis involvement in pediatric immune thrombocytopenia[J].Hematology,2019,24(1):473-479. [31]韩晓丹,周健,喻凤宽,等.利妥昔单克隆抗体和地塞米松联合环磷酰胺治疗复发难治的免疫性血小板减少症[J].中国实验血液学杂志,2016,24(1):162-166. [32]Veglia F,Perego M,Gabrilovich D.Myeloid-derived suppressor cells coming of age[J].Nature Immunology,2018,19(2):108-119. [33]Shao X,Wu B,Cheng L,et al.Distinct alterations of CD68+CD163+M2-like macrophages and myeloid-derived suppressor cells in newly diagnosed primary immune thrombocytopenia with or without CR after high-dose dexamethasone treatment[J].Journal of Translational Medicine,2018,16(1):48. [34]李海文,戴夫,彭琼,等.髓系来源的抑制性细胞免疫学特点及其在自身免疫性疾病中的作用[J].中华微生物学和免疫学杂志,2011,31(7):667-670. [35]吴昊,伊焕发,杨永广.MDSC在自身免疫疾病中的作用[J].中国免疫学杂志,2017,33(3):321-327,332. [36]Liu YW,Qu W,Wang HQ,et al.Number and Function of Myeloid-Derived Suppressor Cells in Patients with Adult Primary Immune Thrombocytopenia[J]. Journal of Experimental Hematology,2018,26(4):1151-1155. [37]Zhou J,Zhou Y,Wen J,et al.Circulating myeloid-derived suppressor cells predict disease activity and treatment response in patients with immune thrombocytopenia[J].Brazilian Journal of Medical&Biological Research,2017,50(2):e5637. [38]Hou Y,Feng Q,Xu M,et al.High-dose dexamethasone corrects impaired myeloid-derived suppressor cell function via Ets1 in immune thrombocytopenia[J].Blood,2016,127(12):1587-1597. [39]Zhang D,Li H,Ma L,et al.The defective bone marrow-derived mesenchymal stem cells in patients with chronic immune thrombocytopenia[J].Autoimmunity,2014,47(8):519-529. [40]Wang X,Yin X,Sun W,et al.Intravenous infusion umbilical cord-derived mesenchymal stem cell in primary immune thrombocytopenia:A two-year follow-up[J].Experimental&Therapeutic Medicine,2017,13(5):2255-2258. [41]Ping Z,Zhang G,Liu X,et al.Mesenchymal stem cells improve platelet counts in mice with immune thrombocytopenia[J].Journal of Cellular Biochemistry,2019,120(5):11274-11283. [42]陶艳玲.小鼠骨髓源间充质干细胞对小鼠ITP模型治疗作用及机制的研究[D].青岛大学,2017. [43]赵霞,丁慧芳,刘国强,等.间充质干细胞体外对ITP患者CD4+CD25+T细胞影响[J].中国免疫学杂志,2013,29(5):490-494. [44]徐玲珑,吴迪炯,邵科钉,等.骨髓间充质干细胞下调免疫性血小板减少症患者CD8+T淋巴细胞及Th1类细胞因子表达的体外研究[J].浙江中医药大学学报,2016,40(4):245-252. [45]Bonasio R,Scimone ML,Schaerli P,et al.Clonal deletion of thymocytes by circulating dendritic cells homing to the thymus[J].Nature Immunology,2006,7(10):1092-100. [46]Ohnmacht C,Pullner A,King SBS,et al.Constitutive ablation of dendritic cells breaks self-tolerance of CD4 T cells and results in spontaneous fatal autoimmunity[J].Journal of Experimental Medicine,2009,206(3):549-559. [47]Quintana FJ,Yeste A,Mascanfroni ID.Role and therapeutic value of dendritic cells in central nervous system autoimmunity[J].Cell Death&Differentiation,2015,22(2):215-224. [48]Akbari O,Dekruyff RH,Umetsu DT.Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen[J].Nature Immunology,2001,2(8):725-731. [49]Munn DH,Sharma MD,Lee JR,et al.Potential Regulatory Function of Human Dendritic Cells Expressing Indoleamine 2,3-Dioxygenase[J].Science,2002,297(5588):1867-1870. [50]Travis MA,Reizis B,Melton AC,et al.Loss of integrin alpha(v)beta8 on dendritic cells causes autoimmunity and colitis in mice[J].Nature,2007,449(7160):361-365. [51]Mascanfroni ID,Yeste A,Vieira SM,et al.IL-27 acts on DCs to suppress the T cell response and autoimmunity by inducing expression of the immunoregulatory molecule CD39[J].Nature Immunology,2013,14(10):1054-1063. [52]Mahnke K,Qian Y,Knop J,et al.Induction of CD4+/CD25+regulatory T cells by targeting of antigens to immature dendritic cells[J].Blood,2003,101(12):4862. [53]Fu J,Zhang A,Ju X.Tolerogenic Dendritic Cells as a Target for the Therapy of Immune Thrombocytopenia[J].Clin Appl Thromb Hemost,2012,18(5):469. [54]Ling Y,Cao X,Yu Z,et al.Circulating dendritic cells subsets and CD4+Foxp3+ regulatory T cells in adult patients with chronic ITP before and after treatment with high-dose dexamethasome[J].European Journal of Haematology,2010,79(4):310-316. [55]Catani L,Sollazzo D,Trabanelli S,et al.Decreased expression of indoleamine 2,3-dioxygenase 1 in dendritic cells contributes to impaired regulatory T cell development in immune thrombocytopenia[J].Annals of Hematology,2013,92(1):67-78. [56]付金秋.耐受性树突状细胞诱导免疫性血小板减少症小鼠免疫耐受的实验研究[D].山东大学,2015. [57]Vito CD,Mikulak J,Mavilio D.On the Way to Become a Natural Killer Cell[J].Frontiers in Immunology,2019(10):1812. [58]魏海明,田志刚.NK细胞的发育分化与功能极化[J].中国免疫学杂志,2014,30(1):14-17. [59]Zhao Z,Yang L,Yang G,et al.Contributions of T Lymphocyte Abnormalities to Therapeutic Outcomes in Newly Diagnosed Patients with Immune Thrombocytopenia[J].PloS One,2015,10(5):e0126601. [60]Talaat RM,Elmaghraby AM,Barakat SS,et al.Alterations in immune cell subsets and their cytokine secretion profile in childhood idiopathic thrombocytopenic purpura(ITP)[J].Clinical & Experimental Immunology,2014,176(2):291-300. [61]Ebbo M,Audonnet S,Grados A,et al.NK cell compartment in the peripheral blood and spleen in adult patients with primary immune thrombocytopenia[J].Clinical Immunology,2017(177):18-28. [62]张玉娇.免疫性血小板减少症患者NK细胞数量及功能研究[D].天津医科大学,2017. [63]阮经艳.探讨成人原发免疫性血小板减少症患者外周血淋巴细胞亚群变化及其临床意义[D].昆明医科大学,2017. [64]赵雅境.调节单核/巨噬系统和CD4~+T细胞系统在ITP免疫耐受重建中的作用研究[D].山东大学,2019. [65]刘缦缦,刘方媛,刘禄社,等.原发免疫性血小板减少症患者骨髓组织中T细胞和巨噬细胞表达水平及临床意义[J].中华实用诊断与治疗杂志,2019,33(2):117-119. [66]Provan D,Arnold DM,Bussel JB,et al.Updated international consensus report on the investigation and management of primary immune thrombocytopenia[J].Blood Advances,2019,3(22):3780-3817. [67]中华医学会血液学分会血栓与止血学组.成人原发免疫性血小板减少症诊断与治疗中国指南(2020年版)[J].中华血液学杂志,2020,41(8):617-623. [68]Feng Q,Xu M,Yu YY,et al.High-dose dexamethasone or all-trans-retinoic acid restores the balance of macrophages towards M2 in immune thrombocytopenia[J].Journal of Thrombosis&Haemostasis,2017,15(9):1845-1858.